Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant carboplatin + paclitaxel for locally advanced vulvar carcinoma
2019-003104-12Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and carboplatin in Vulval carcinoma and cancer, sponsored by Netherlands Cancer Institute. Primary endpoint: Primary response rate. Started Nov 2019; status: active.
02
Drugs
paclitaxelcarboplatin
03
Conditions
Vulval carcinomacancer
Beyond the preview
Go deeper on 2019-003104-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003104-12.